Retrophin to Present at Upcoming Investor Conferences
February 19, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in February and March:...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2019
October 11, 2019 16:05 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from the Phase 2 DUET Study examining the impact of sparsentan on quality of...
Retrophin Announces Appointment of Peter Heerma as Chief Commercial Officer
October 01, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Peter Heerma as chief commercial officer, effective immediately. In this newly created...
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 14, 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global...